Recent Updates
Recently added Catalysts
EW Positive Sentiment

Edwards Lifesciences to Host Earnings Conference Call on July 23, 2026

Thursday, July 16, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Edwards Lifesciences plans to announce its operating results for Q2 2026 on July 23. The company will host a conference call at 5:00 p.m. ET to discuss these results. Participants can join the call via phone or access it through the company's Investor Relations website.
Price reaction · baseline $87.27 (2026-07-15 close) · hit pre-market · clean, no other EW news in the window
day 0 close
+0.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Edwards Lifesciences is actively engaging with investors.
  • The upcoming conference call indicates transparency in operations.
  • The announcement of operating results shows proactive communication.

Full Press Release Details

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2026 after the market closes on Thursday July 23, and will host a conference call at 5:00 p.m. ET that day to discuss those results.To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com.About Edwards LifesciencesE

Frequently Asked Questions

When will Edwards Lifesciences announce its Q2 results?

Edwards Lifesciences will announce its Q2 results on July 23, 2026.

What time is the earnings conference call?

The earnings conference call is scheduled for 5:00 p.m. ET on July 23.

How can I participate in the conference call?

To participate, dial (877) 704-2848 or (201) 389-0893.

Where can I find the archived conference call?

The archived call will be available on the Investor Relations section of Edwards' website.

ShareAdd on Google
Tags: EW Viatris Investor Conferences Healthcare Edwards Lifesciences earnings call Q2 results conference call NYSE: EW
Last updated: Jul 16, 2026

Biotech snapshot

Cash runway
$4253M liquidity · $0M/mo burn
Low dilution risk
Lead asset
KetotifenPhase 3
Widespread Chronic Pain →